|
10084
|
ERVEBO
|
Ebola
|
Hemorrhagic
|
Zaire ebolavirus
|
negative-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Merck & Co. Inc.
|
2019
|
USA
|
18 years and above
|
Single dose
|
Intramuscular
|
NA
|
Zaire Ebola virus glycoprotein
|
NA
|
US FDA, EMA
|
NA
|
NA
|
V920, rVSV-G-ZEBOV-GP, rVSV-ZEBOV
|
NA
|
NA
|
https://www.cdc.gov/vhf/ebola/clinicians/vaccine/index.html
|
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2817%2930313-4/fulltext
|
|
10085
|
Ad26.ZEBOV
|
Ebola
|
Hemorrhagic
|
Zaire ebolavirus
|
negative-sense, single-stranded RNA
|
Recombinant viral vector
|
Approved
|
Janssen Pharmaceutical
|
2020
|
USA
|
1 year and above
|
Single dose of Zabdeno on day 0 followed by 0.5mL dose of Mvabea post 8 week
|
Intramuscular
|
NA
|
Adenovirus type 26 encoding the Zaire ebolavirus, Mayinga variant glycoprotein
|
NA
|
US FDA, EMA
|
NA
|
NA
|
MVA-BN-Filo
|
NA
|
NCT02509494
|
https://clinicaltrials.gov/ct2/show/NCT02509494
|
https://clinicaltrials.gov/ct2/show/NCT05284097
|
|
10086
|
YF-Vax
|
Yellow fever
|
Hemorrhagic
|
Yellow fever virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Sanofi Pasteur
|
NA
|
France
|
9 months and above
|
Single dose
|
Subcutaneous
|
NA
|
17D-204 strain of yellow fever virus
|
Culturing 17D-204 strain of yellow fever virus in living avian leukosis virus-free (ALV-free) chicken embryos
|
US FDA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.fda.gov/media/76015/download
|
https://www.fda.gov/media/76015/download
|
|
10087
|
CYD-TDV Dengvaxia
|
Dengue fever
|
Hemorrhagic
|
Dengue virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Sanofi Pasteur
|
2015
|
France
|
9 - 45 years
|
3 doses 6 months apart
|
Subcutaneous
|
NA
|
Dengue virus serotypes (1, 2, 3 and 4)
|
17D vaccine vector expressing genes of DENV-1, 2, 3, or 4
|
US FDA
|
NA
|
NA
|
NA
|
30684747
|
NCT02747927
|
https://www.sciencedirect.com/science/article/pii/S1201971219300402
|
https://www.fda.gov/media/124379/download
|
|
10200
|
Ad5-EBOV
|
Ebola
|
Hemorrhagic
|
Zaire ebolavirus
|
negative-sense, single-stranded RNA
|
Non-replicating viral vector
|
Phase 1
|
National Institute of Health
|
2010
|
USA
|
18 - 50 years
|
NA
|
Intramuscular
|
NA
|
Ebola virus envelope glycoprotein
|
NA
|
NA
|
National Institute of Allergy and Infectious Diseases
|
NA
|
NA
|
27764560
|
NCT00374309
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287303/
|
https://www.precisionvaccinations.com/vaccines/ad5-ebov-ebola-vaccine#:~:text=CanSinBio%20Ad5%2DEBOV%20is%20an,type%2D5%20vector%20immune%20response.
|
|
10201
|
DNA
|
Ebola
|
Hemorrhagic
|
Zaire ebolavirus
|
negative-sense, single-stranded RNA
|
DNA based vaccine
|
Phase 1
|
National Institute of Health
|
2003
|
USA
|
18 - 44 years
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
National Institute of Allergy and Infectious Diseases
|
NA
|
NA
|
27764560
|
NCT00072605
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287303/
|
NA
|
|
10202
|
rVSV-EBOV
|
Ebola
|
Hemorrhagic
|
Zaire ebolavirus
|
negative-sense, single-stranded RNA
|
Recombinant viral vector
|
Phase 1
|
Merck & Co. Inc.
|
2014
|
USA
|
18 - 65 years
|
NA
|
Intramuscular
|
NA
|
Zaire Ebola virus glycoprotein
|
Vesicular Stomatitis Virus based
|
NA
|
National Institute of Allergy and Infectious Diseases
|
NA
|
NA
|
27764560
|
NCT02280408
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287303/
|
NA
|
|
10203
|
Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO)/ChAd3-EBO-Z
|
Ebola
|
Hemorrhagic
|
Zaire ebolavirus
|
negative-sense, single-stranded RNA
|
Recombinant viral vector
|
Phase 1
|
National Institute of Allergy and Infectious Diseases
|
2014
|
USA
|
18 - 65 years
|
NA
|
Intramuscular
|
NA
|
Wild type glycoproteins from Zaire and Sudan strains of Ebolavirus
|
Chimpanzee Adenovirus Vector expressing Zaire and sudan strain glycoprotein
|
NA
|
NA
|
NA
|
NA
|
27764560
|
NCT02231866
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287303/
|
NA
|
|
10204
|
HPIV3-EBO-Z ( HPIV3-EbovZ GP Vaccine)
|
Ebola
|
Hemorrhagic
|
Zaire ebolavirus
|
negative-sense, single-stranded RNA
|
Virus like particle
|
Phase 1
|
Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health
|
2015
|
USA
|
18 - 50 years
|
NA
|
Intranasal
|
NA
|
Zaire Ebola virus glycoprotein
|
Live-attenuated human Parainfluenza virus type 3 vectored vaccine expressing Ebolavirus Zaire glycoprotein
|
NA
|
National Institute of Allergy and Infectious Diseases
|
NA
|
NA
|
27764560
|
NCT02564575
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287303/
|
NA
|
|
10205
|
KIRIM-KONGO-VAX
|
Crimean-Congo haemorrhagic fever
|
Hemorrhagic
|
Nairovirus
|
negative-sense, single-stranded RNA
|
NA
|
Phase 1
|
The Scientific and Technological Research Council of Turkey
|
2017
|
Turkey
|
18 - 55 years
|
NA
|
Subcutaneous, Intramuscular
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT03020771
|
https://clinicaltrials.gov/ct2/show/NCT03020771?cond=Crimean-Congo+hemorrhagic+fever&draw=2&rank=1
|
https://ichgcp.net/clinical-trials-registry/NCT03020771
|
|
10206
|
GEO-EM05
|
Marburg hemorrhagic fever
|
Hemorrhagic
|
Marburg virus
|
negative-sense, single-stranded RNA
|
Virus like particle
|
Phase 1
|
GeoVax Labs Inc.
|
NA
|
USA
|
NA
|
NA
|
Intramuscular
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.biospace.com/article/geovax-announces-100-percent-protection-data-from-marburg-virus-vaccine-study/
|
NA
|
|
10207
|
AVI-6003
|
Marburg hemorrhagic fever
|
Hemorrhagic
|
Marburg virus
|
negative-sense, single-stranded RNA
|
NA
|
Phase 1
|
Sarepta Therapeutics Inc.
|
2012
|
USA
|
18 - 55 years
|
NA
|
Intravenous
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT01353040
|
https://clinicaltrials.gov/ct2/show/NCT01353040?cond=Marburg+hemorrhagic+fever&draw=2&rank=1
|
NA
|
|
10208
|
cAd3 Marburg (VRC-MARADC087-00-VP)
|
Marburg hemorrhagic fever
|
Hemorrhagic
|
Marburg virus
|
negative-sense, single-stranded RNA
|
Recombinant viral vector
|
Phase 1
|
National Institute of Allergy and Infectious Diseases
|
2021
|
USA
|
18 - 50 years
|
Single dose
|
Intramuscular
|
NA
|
Marburg wild type glycoprotein
|
NA
|
US FDA
|
US Military HIV Research Program
|
NA
|
NA
|
NA
|
NCT03475056
|
https://clinicaltrials.gov/ct2/show/NCT03475056?cond=Marburg+hemorrhagic+fever&draw=2&rank=3
|
NA
|
|
10209
|
XRX-001 Inactivated yellow fever vaccine
|
Yellow fever
|
Hemorrhagic
|
Yellow fever virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 1
|
GE Healthcare
|
2016
|
USA
|
18 - 49 years
|
NA
|
NA
|
Aluminum (alum)
|
Yellow fever virus
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT00995865
|
https://clinicaltrials.gov/ct2/show/NCT00995865?recrs=abde&cond=yellow+fever&phase=0123&draw=2&rank=4
|
NA
|
|
10210
|
DENV-1 PIV
|
Dengue fever
|
Hemorrhagic
|
Dengue virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 1
|
US Army Medical Research and Development Command
|
2015
|
USA
|
18 - 50 years
|
2 doses 28 days apart
|
Intramuscular
|
NA
|
Dengue virus serotypes -1
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT01502735
|
https://clinicaltrials.gov/ct2/show/NCT01502735?recrs=abde&cond=dengue+fever&phase=0123&draw=2&rank=5
|
NA
|
|
10211
|
rDEN3delta30/31-7164
|
Dengue fever
|
Hemorrhagic
|
Dengue virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 1
|
National Institute of Allergy and Infectious Diseases
|
2013
|
USA
|
18 - 50 years
|
NA
|
Subcutaneous
|
NA
|
Dengue virus serotypes -3
|
NA
|
NA
|
Johns Hopkins Bloomberg School of Public Health
|
NA
|
NA
|
NA
|
NCT00831012
|
https://clinicaltrials.gov/ct2/show/NCT00831012?recrs=abde&cond=dengue+fever&phase=0123&draw=2&rank=12
|
NA
|
|
10212
|
MV-LASV (V182-001)
|
Lassa fever
|
Hemorrhagic
|
Lassa virus
|
negative-sense, single-stranded RNA
|
Live-attenuated
|
Phase 1
|
Themis Bioscience
|
2021
|
Belgium
|
18 - 55 years
|
2 doses 28 days apart
|
Intramuscular
|
NA
|
Measles Schwarz virus strain for prophylaxis of Lassa infection
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT04055454
|
https://clinicaltrials.gov/ct2/show/NCT04055454?cond=Lassa+fever&draw=2&rank=10
|
NA
|
|
10294
|
cAd3-EBO
|
Ebola
|
Hemorrhagic
|
Zaire ebolavirus
|
negative-sense, single-stranded RNA
|
Recombinant viral vector
|
Phase 2
|
Centre Hospitalier Universitaire Vaudois
|
2014
|
Switzerland
|
18 - 65 years
|
NA
|
Intramuscular
|
NA
|
Zaire Ebola virus glycoprotein
|
Chimpanzee Adenovirus Vector expressing Zaire strain glycoprotein
|
NA
|
NA
|
NA
|
NA
|
27764560
|
NCT02289027
|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287303/
|
NA
|
|
10295
|
DSV4
|
Dengue fever
|
Hemorrhagic
|
Dengue virus
|
positive-sense, single-stranded RNA
|
Subunit vaccine
|
Phase 2
|
Panacea Biotec Ltd
|
NA
|
India
|
2 - 60 years
|
NA
|
NA
|
NA
|
Chimeric protein containing vHBsAg,DS, unique tetravalent dengue antigen
|
Produced using the methylotrophic yeast Pichia pastoris
|
NA
|
NA
|
NA
|
NA
|
30684747
|
NA
|
https://www.sciencedirect.com/science/article/pii/S1201971219300402
|
NA
|
|
10363
|
STAMARiL
|
Yellow fever
|
Hemorrhagic
|
Yellow fever virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 3
|
Sanofi Pasteur
|
NA
|
France
|
10 months
|
Single dose
|
Subcutaneous
|
NA
|
17D-204 strain of yellow fever virus
|
Produced in specified pathogen-free chick embryos
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.sanofipasteur.co.uk/-/media/ems/conditions/vaccines/brands/oneportal-ie/pdf/105_stamaril_mah_address_update_12_2017_uk.pdf
|
NA
|
|
10364
|
TAK-003
|
Dengue fever
|
Hemorrhagic
|
Dengue virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 3
|
Takeda Pharmaceutical Company Limited
|
NA
|
USA
|
4 - 16 years
|
NA
|
Subcutaneous
|
NA
|
Dengue virus serotypes (1, 2, 3 and 4)
|
Mammalian cell vero culture
|
NA
|
NA
|
NA
|
TDV
|
30684747
|
NA
|
https://www.sciencedirect.com/science/article/pii/S1201971219300402
|
NA
|
|
10365
|
TV-003/005
|
Dengue fever
|
Hemorrhagic
|
Dengue virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 3
|
Merck & Co. Inc.
|
NA
|
Brazil
|
2 - 59 years
|
NA
|
Subcutaneous
|
NA
|
Dengue virus serotypes (1, 2, 3 and 4)
|
Mammalian cell vero culture
|
NA
|
National Institute of Allergy and Infectious Diseases
|
NA
|
TetraVax-DV
|
30684747
|
NCT02406729
|
https://www.sciencedirect.com/science/article/pii/S1201971219300402
|
https://clinicaltrials.gov/ct2/show/NCT02406729
|
|
10379
|
Bulgarian vaccine
|
Crimean-Congo haemorrhagic fever
|
Hemorrhagic
|
Nairovirus
|
negative-sense, single-stranded RNA
|
Inactivated
|
Preclinical
|
NA
|
1974
|
Union of Soviet Socialist Republics
|
16 years and above
|
NA
|
Subcutaneous
|
Aluminum (aluminium hydroxide)
|
NA
|
Prepared from brain tissue of CCHFV infected newborn mice
|
NA
|
NA
|
NA
|
Zabdeno, Mvabea
|
32461819
|
NA
|
https://www.liebertpub.com/doi/10.1089/biores.2019.0057
|
https://www.ema.europa.eu/en/documents/product-information/zabdeno-epar-product-information_en.pdf
|